Timing for Stopping Spironolactone Before Conception

Rationale for Discontinuation Timeline

The American College of Rheumatology recommends stopping medications with potential teratogenic effects well before conception 1

Methotrexate should be discontinued 1-3 months before conception, as recommended by guidelines 2, 3
Mycophenolate should be discontinued 6 weeks before conception, according to guidelines 4, 5
Cyclophosphamide should be discontinued 3 months before conception, as recommended by guidelines 2, 3
Anabolic androgenic agents should be discontinued 2 months before conception, according to guidelines 6, 7, 8

Women taking spironolactone for hyperandrogenic conditions should discuss family planning with their healthcare provider well in advance and consider alternative treatments that are pregnancy-compatible if conception is desired in the near future 1

For women with conditions requiring anti-androgenic therapy who are planning pregnancy, transitioning to pregnancy-compatible medications for the underlying condition and close monitoring of the underlying condition during the pre-conception period are recommended 1

Spironolactone is a synthetic 17-lactone steroid with antagonistic effects on androgen receptors that has been used off-label for acne treatment for over 30 years, classified as pregnancy category C, and when administered in high doses to rats, it has been found to cause feminization of male fetuses, according to the American Academy of Dermatology 9
The most common side effect in patients taking spironolactone is menstrual irregularities, occurring in 15-30% of patients, as reported by the American Academy of Dermatology 9
Other side effects include breast tenderness (3-5%), dizziness (3-4%), nausea (2-4%), headache (2%), polyuria (1-2%), and fatigue (1-2%), as noted by the American Academy of Dermatology 9

For acne treatment specifically, consider pregnancy-safe alternatives such as non-hormonal systemic treatments if necessary, as suggested by the American Academy of Dermatology 9

The American Diabetes Association recommends transitioning to pregnancy-safe antihypertensives, such as methyldopa, nifedipine, labetalol, or clonidine, before conception, and avoiding ACE inhibitors and angiotensin receptor blockers entirely 10
Target blood pressure of 110-135/85 mmHg during pregnancy to reduce maternal hypertension risk while minimizing fetal growth impairment 10
Achieving disease control, whether hypertension, heart failure, or hyperandrogenic conditions, before conception is crucial to optimize pregnancy outcomes, as suggested by the American Gastroenterological Association 11
The American College of Obstetricians and Gynecologists implies the importance of using reliable contraception until a pregnancy-safe treatment plan is established 10